Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

EphB receptor activity suppresses colorectal cancer progression

A Corrigendum to this article was published on 11 August 2005


Most sporadic colorectal cancers are initiated by activating Wnt pathway mutations1, characterized by the stabilization of β-catenin and constitutive transcription by the β-catenin/T cell factor-4 (Tcf-4) complex2,3. EphB guidance receptors are Tcf4 target genes that control intestinal epithelial architecture through repulsive interactions with Ephrin-B ligands4,5. Here we show that, although Wnt signalling remains constitutively active, most human colorectal cancers lose expression of EphB at the adenoma–carcinoma transition. Loss of EphB expression strongly correlates with degree of malignancy. Furthermore, reduction of EphB activity accelerates tumorigenesis in the colon and rectum of ApcMin/+ mice, and results in the formation of aggressive adenocarcinomas. Our data demonstrate that loss of EphB expression represents a critical step in colorectal cancer progression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: EPHB2 is a β-catenin/Tcf-4 target gene but it is downregulated in advanced colorectal tumours and cell lines.
Figure 2: EphB2 and EphB4 are downregulated during CRC progression.
Figure 3: EphB2 downregulation correlates with higher histological tumour grade.
Figure 4: Accelerated colorectal tumorigenesis in Apc Min/+ mice expressing Δ cy EphB2 transgene or bearing Ephb3 -null alleles.

Similar content being viewed by others


  1. Bienz, M. & Clevers, H. Linking colorectal cancer to Wnt signaling. Cell 103, 311–320 (2000)

    Article  CAS  Google Scholar 

  2. Korinek, V. et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275, 1784–1787 (1997)

    Article  CAS  Google Scholar 

  3. Morin, P. J. et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275, 1787–1790 (1997)

    Article  CAS  Google Scholar 

  4. Batlle, E. et al. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111, 251–263 (2002)

    Article  CAS  Google Scholar 

  5. van de Wetering, M. et al. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111, 241–250 (2002)

    Article  CAS  Google Scholar 

  6. Kuhnert, F. et al. Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc. Natl Acad. Sci. USA 101, 266–271 (2004)

    Article  ADS  CAS  Google Scholar 

  7. Powell, S. M. et al. APC mutations occur early during colorectal tumorigenesis. Nature 359, 235–237 (1992)

    Article  ADS  CAS  Google Scholar 

  8. Sparks, A. B., Morin, P. J., Vogelstein, B. & Kinzler, K. W. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58, 1130–1134 (1998)

    CAS  PubMed  Google Scholar 

  9. Shitoh, K. et al. Frequent activation of the beta-catenin-Tcf signaling pathway in nonfamilial colorectal carcinomas with microsatellite instability. Genes Chromosom. Cancer 30, 32–37 (2001)

    Article  CAS  Google Scholar 

  10. Su, L. K. et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256, 668–670 (1992)

    Article  ADS  CAS  Google Scholar 

  11. Moser, A. R., Pitot, H. C. & Dove, W. F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247, 322–324 (1990)

    Article  ADS  CAS  Google Scholar 

  12. Yamada, Y. et al. Microadenomatous lesions involving loss of Apc heterozygosity in the colon of adult Apc(Min/ + ) mice. Cancer Res. 62, 6367–6370 (2002)

    CAS  PubMed  Google Scholar 

  13. Huusko, P. et al. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nature Genet. 36, 979–983 (2004)

    Article  CAS  Google Scholar 

  14. Sancho, E., Batlle, E. & Clevers, H. Live and let die in the intestinal epithelium. Curr. Opin. Cell Biol. 15, 763–770 (2003)

    Article  CAS  Google Scholar 

  15. Mao, W. et al. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res. 64, 781–788 (2004)

    Article  CAS  Google Scholar 

  16. Munarini, N. et al. Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase. J. Cell Sci. 115, 25–37 (2002)

    CAS  PubMed  Google Scholar 

  17. Gregorieff, A., Grosschedl, R. & Clevers, H. Hindgut defects and transformation of the gastro-intestinal tract in Tcf4(- / - )/Tcf1(- / - ) embryos. EMBO J. 23, 1825–1833 (2004)

    Article  CAS  Google Scholar 

  18. Orioli, D., Henkemeyer, M., Lemke, G., Klein, R. & Pawson, T. Sek4 and Nuk receptors cooperate in guidance of commissural axons and in palate formation. EMBO J. 15, 6035–6049 (1996)

    Article  CAS  Google Scholar 

  19. Roose, J. et al. Synergy between tumour suppressor APC and the beta-catenin-Tcf4 target Tcf1. Science 285, 1923–1926 (1999)

    Article  CAS  Google Scholar 

  20. Lal, G. et al. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res. 61, 6131–6136 (2001)

    CAS  PubMed  Google Scholar 

Download references


We thank A. Ziemiecki for EphB4 antiserum, and A. García de Herreros and C. Francí for help with mouse experiments.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Hans Clevers.

Ethics declarations

Competing interests

Reprints and permissions information is available at The authors declare no competing financial interests.

Supplementary information

Supplementary Methods

Detailed immunohistochemistry and in situ hybridisation protocols. (PDF 20 kb)

Supplementary Figure Legends

Legends for Supplementary Figures S1-S11. (PDF 74 kb)

Supplementary Figure S1

Example of loss of EphB2 expression in CRC liver metastasis. (PDF 206 kb)

Supplementary Figure S2

Examples of colorectal lesions classified in each EphB group. (PDF 306 kb)

Supplementary Figure S3

Statistical analysis of EphB2 expression in CRC lesions. (PDF 31 kb)

Supplementary Figure S4

Statistical analysis of EphB4 expression in CRC lesions. (PDF 30 kb)

Supplementary Figure S5

Statistical analysis of the correlation between EphB2 and EphB4 expression in CRC lesions. (PDF 11 kb)

Supplementary Figure S6

Example of colorectal tumour with downregulated EphB2 protein but high levels of EphB2 mRNA. (PDF 243 kb)

Supplementary Figure S7

Examples of in situ hybridisation with EphB2 and EphB3 probes on carcinomas with different histological grade. (PDF 149 kb)

Supplementary Figure S8

EphB4 expression in intestine of EphB2 and -B3 knock-out mice. EphB4 mRNA levels in CRC cell lines upon induction of dominant negative TCF factors. (PDF 177 kb)

Supplementary Figure 9

Examples of EphB4 expression patterns in CRC lesions at different stages. (PDF 313 kb)

Supplementary Figure S10

Nuclear β-catenin accumulation and expression of EphB2 and EphB4 in colonic microlesions of APCmin/+ mice. (PDF 205 kb)

Supplementary Figure S11

Features of δcyEphB2;ApcMin/+ tumours including nuclear β-catenin accumulation. (PDF 197 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Batlle, E., Bacani, J., Begthel, H. et al. EphB receptor activity suppresses colorectal cancer progression. Nature 435, 1126–1130 (2005).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing